The year 2013 has been a pivotal economic period marked with bullishness, with investors gaining confidence in stocks and the market as a whole. A critical pillar in this historic rally has been the recovery of the financial sector, more specifically through the rise of regional banks. Despite this sector's popularity and outperformance, there are still opportunities for buyers to find value and continue to make money in this industry. One such opportunity lies in a regional bank by the name of SunTrust (STI). SunTrust Bank has performed exceptionally well since the depths of the financial crisis, and is better prepared to tackle the interest rate environment going forward. Wall Street, however, hasn't been rewarding SunTrust with the popularity, and price, that it deserves. Investors shouldn't wait to take advantage of this opportunity to own a high quality bank at a substantial discount to its intrinsic value.
Overview
SunTrust Banks, Inc. is a regional financial service company with over $171 billion in assets and operations primarily in the southeast. The company provides deposit, credit and investment services to a wide portfolio of clients in both the retail and institutional market. With a market cap of close to $18 billion, SunTrust is a relatively large player in the regional financial sector. This allows the company to expand services and offer higher quality products as the economy improves and business confidence recovers.
Best Integrated Utility Stocks To Own For 2016: Elecsys Corporation(ESYS)
Elecsys Corporation provides data acquisition systems, machine to machine (M2M) communication technology solutions, and custom electronic equipment for critical industrial applications in the United States and internationally. The company designs and manufactures wireless remote monitoring and telemetry solutions to the energy infrastructure sector, as well as other industrial markets under the Pipeline Watchdog and NTG brand names. It also provides process monitoring, data communication, and cyber security solutions under the SensorCast, Director, and zONeGUARD brand names; smart asset tagging solutions based on radio frequency identification (RFID) technologies, which include custom tags, readers, and software under the brand name of eXtremeTAG; custom electronic design and manufacturing services (EDMS) under the DCI brand name; and ultra-rugged handheld computing solutions, as well as handheld computers, printers, peripherals, and application software under the brand na me of Radix. In addition, the company designs, manufactures, and tests a range of electronic assemblies, including circuit boards, high-frequency electronic modules, microelectronic assemblies, and turn-key products; and provides liquid crystal displays (LCDs) devices and modules, and hardware and software design services to its original equipment manufacturers (OEMs) partners, as well as offers integrated data collection and reporting solutions. It primarily serves energy infrastructure, safety and security systems, industrial controls, irrigation and water management, transportation, military, and aerospace markets. Elecsys Corporation was founded in 1991 and is headquartered in Olathe, Kansas.
Advisors' Opinion:- [By John Udovich]
Small cap machine-to-machine (M2M) stock Elecsys Corp (NASDAQ: ESYS) jumped 8.99% yesterday and is up 254% over the past year, meaning it might be time to take a closer look at the stock and its performance verses other small cap M2M stocks like Digi International Inc (NASDAQ: DGII), Numerex Corp (NASDAQ: NMRX) and Sierra Wireless, Inc (NASDAQ: SWIR). First of all though, I should mention that machine-to-machine (M2M) broadly refers to technologies that allow both wireless and wired systems to communicate with other devices of the same type and this can be through any type of technology ranging from instruments to networks to applications that create connections between devices.
Hot Regional Bank Stocks To Invest In 2015: Ruth's Hospitality Group Inc.(RUTH)
Ruth?s Hospitality Group, Inc., together with its subsidiaries, operates restaurants in the United States and internationally. It operates the Ruth?s Chris Steak House, Mitchell?s Fish Market, Columbus Fish Market, Mitchell?s Steakhouse, and Cameron?s Steakhouse restaurant concepts in the full-service dining industry. The company?s restaurants cater to families, special occasion diners, and business clientele. As of December 27, 2009, it owned or operated 152 restaurants, including 64 company-owned Ruth?s Chris Steak House Company restaurants, 66 Ruth?s Chris Steak House franchise restaurants, 19 company-owned Mitchell?s Fish Markets, and 3 company-owned Mitchell?s Steakhouse restaurants. The company was formerly known as Ruth?s Chris Steak House, Inc. and changed its name to Ruth?s Hospitality Group, Inc. in February 2008. Ruth?s Hospitality Group, Inc. was founded in 1965 and is headquartered in Heathrow, Florida.
Advisors' Opinion:- [By Timothy Green]
Another steakhouse operator which recently started paying a dividend is Ruth's Hospitality Group (NASDAQ: RUTH ) . Ruth's is a small company that operates a handful of restaurant concepts, mainly steakhouses. In 2012 the company recorded about $400 million in revenue and $16 million in net income. The stock trades for about 27 times earnings.
- [By Seth Jayson]
When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to Ruth's Hospitality Group (Nasdaq: RUTH ) .
- [By Sally Jones]
Averaging 228% on shares bought, a high gainer in this portfolio is Ruth��s Hospitality Group Inc. (RUTH), up 81% over 12 months:
Robert Karr, Joho Capital
Hot Regional Bank Stocks To Invest In 2015: Brown(n)
N Brown Group plc operates as an Internet and catalogue home shopping company in the United Kingdom. The company principally offers womenswear, menswear, footwear, household, and electrical products, as well as provides insurance services. It also operates in the Republic of Ireland, Germany, and the United States. The company was founded in 1859 and is based in Manchester, the United Kingdom.
Advisors' Opinion:- [By Jason Cunningham]
"Whether it's LinkedIn (NYSE: LNKD), Pandora (NYSE: P), Yelp (NYSE: YELP), you go back to Salesforce (NYSE: CRM), Workday (NYSE: WDAY), NetSuite (NYSE: N), I think we've proven to the clients in that industry we're a better partner, and now it's up to us to execute, 'cause Thursday is all about Twitter and the investors. It's not about us."
Hot Regional Bank Stocks To Invest In 2015: Horizon Pharma Inc (HZNP)
Horizon Pharma, Inc. (Horizon), incorporated on March 23, 2010, is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. On April 23, 2011, the United States Food and Drug Administration, approved DUEXIS (formerly HZT-501), a tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill. The Company��s other product, LODOTRA (NP-01), is a programmed release formulation of low-dose prednisone that is marketed in Europe by the Company��s distribution partner, Mundipharma International Corporation Limited (Mundipharma). As of December 31, 2010, Horizon completed multiple Phase III clinical trials of LODOTRA. In addition to these product candidates, the Company has a pipeline of earlier-stage product candidates to treat pain-related diseases and chronic inflammation. On April 1, 2010, Horizon effected a recapitalization and acquisition pursuant to which Horizon Pharma, Inc. became a holding company, that operates through its wholly owned subsidiaries, Horizon Pharma USA, Inc. (formerly Horizon Therapeutics, Inc.) and Horizon Pharma AG (formerly Nitec Pharma AG (Nitec)).
DUEXIS
DUEXIS is a combination of 800 milligram ibuprofen and 26.6 milligram famotidine in a single pill and is indicated for the relief of signs and symptoms of rheumatoid arthritis (RA), and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal (GI), ulcers in patients who are taking ibuprofen for those indications. The Company has completed two Phase III clinical trials in a total of over 1,500 patients with mild to moderate pain or arthritis that demonstrated a significant reduction in the incidence of non-steroidal anti-inflammatory drugs (NSAID)-induced upper GI ulcers when treated with DUEXIS versus ibuprofen alone.
LODOTRA
LODOTRA is a programmed release formulation of low-dose prednisone, a well-established drug use! d to inhibit the production of various pro-inflammatory cytokines, which are proteins associated with joint inflammation in RA. LODOTRA has received regulatory approval in Europe for the treatment of moderate to severe, active RA in adults when accompanied by morning stiffness. As of December 31, 2010, the Company had completed two pivotal Phase III clinical trials of LODOTRA in a total of over 600 patients with RA. The first pivotal Phase III trial supported the approval of LODOTRA in Europe in March 2009, where it is approved for marketing in 14 European countries. LODOTRA achieved significant results and met the primary endpoint in each of the two pivotal Phase III clinical trials. Its LODOTRA product was developed and is owned by Horizon Pharma AG. As of December 31, 2010, the Company markets LODOTRA in Europe through three separate agreements. Pursuant to two separate agreements, it granted Merck Serono GmbH and Merck GesmbH, an affiliate of Merck Serono, the rights to distribute and market LODOTRA in each of Germany and Austria, respectively, and pursuant to the third agreement, it granted Mundipharma rights to distribute and market LODOTRA in the rest of Europe. The Company also has a manufacturing and supply agreement with Jagotec AG under which Jagotec or its affiliates manufacture and supply LODOTRA to the Company as bulk tablets.
The Company competes with Pfizer Inc., Pozen Inc., Abbott Laboratories and Amgen Inc.
Advisors' Opinion:- [By Bryan Murphy]
After a 16% rally on Tuesday, it would be understandable is a newcomer wanted to steer clear of Horizon Pharma Inc. (NASDAQ:HZNP). After all, how much more upside can there be for this fairly typical small cap biotech stock. Yet, HZNP may well be one of the rare exceptions to the "tough to follow-through" tendency.
For those not familiar, HZNP is a biopharma name with a couple of rheumatoid arthritis, COPD, and asthma drugs on the market... Duexis, and Rayos. There's a third drug in the pipeline - Lodotra, for polymyalgia rheumatica, though it's already approved as a treatment for RA.� Either way, Horizon Pharma Inc. is unique in the sense that though it's a small biopharma company, it's at least driving revenue with a handful of marketable products.
The pipeline and portfolio are secondary at this point, however. What matters most to traders now is whether or not there's actually any upside left to tap into with Horizon Pharma. The answer is, it depends.
Given just the nearby daily chart, no, it looks like HZNP has burned up all of its fuel. Aside from the fact that it's overextended now, Tuesday's volume spike also implies anybody who was thinking about buying went ahead and took the plunge. That may well mean nobody is left to keep buying tomorrow. There may well be, however, plenty of nervous-Nellie profit-takers ready to head for the exit.
The assessment changes quite a bit when you zoom out to a longer-term chart of Horizon Pharma, though.
While this won't allow the stock to sidestep a near-term pullback, Tuesday's pop was something a game-changer for the long-term chart. The move shook the stock out of a narrow range that had trapped the stock between $2.80 and $2.12 for the last ten months.
The proverbial "so what" is, with nearly a years' worth of pent-up energy finally being unleashed, we're nowhere near the end of the final resting place. Once we burn off this initial, knee-jerk reaction to the - [By Lisa Levin]
Horizon Pharma (NASDAQ: HZNP) shares gained 24.15% to $18.23 after the company announced its plans to acquire privately held Vidara Therapeutics International for around $660 million.
- [By Jake L'Ecuyer]
Top losers in the sector included Horizon Pharma (NASDAQ: HZNP), off 9.5 percent, and Anacor Pharmaceuticals (NASDAQ: ANAC), down 8.2 percent.
Top Headline
The Greenbrier Companies (NYSE: GBX) reported a 13% gain in its fiscal second-quarter earnings. Greenbrier's quarterly profit surged to $15.6 million, or $0.50 per share, versus a year-ago profit of $13.8 million, or $0.45 per share. Excluding one-time items, it earned $0.51 per share. Its revenue climbed 88% to $502.2 million. However, analysts were expecting earnings of $0.60 per share on revenue of $508.69 million. - [By Jake L'Ecuyer]
Leading and Lagging Sectors
Wednesday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Horizon Pharma (NASDAQ: HZNP) and Pernix Therapeutics Holdings (NASDAQ: PTX). In trading on Wednesday, telecommunications services shares were relative laggards, down on the day by about 0.39 percent. Top decliners in the sector included Shenandoah Telecommunications Co (NASDAQ: SHEN), off 3.3 percent, and CalAmp (NASDAQ: CAMP), down around 2.4 percent.
Hot Regional Bank Stocks To Invest In 2015: Naturalnano Inc (NNAN)
NaturalNano, Inc. (NaturalNano), incorporated on February 18, 2000, is engaged in the development and commercialization of material science technologies with an emphasis on additives to polymers and other industrial and consumer products by taking advantage of technology advances developed in-house. During the year ended December 31, 2011,the Company��s activities are directed toward research, development, production and marketing of its technologies relating to the treatment and separation of nanotubes from halloysite clay and the development of related commercial applications for cosmetics, health and beauty products, and polymers, plastics and composites.
The company��s halloysite natural tube (HNT) products involve filling HNTs with active agents for use in the polymer composites, health and beauty, household product, and agrichemical industries. The filled tube product contains a material of interest within the tubes, such as an antimicrobial compound to provide antimicrobial properties to the resulting polymer composite material. The filled-tube products will focus on the utilization of the tubular nature of the halloysite nanotubes, by filling or adsorbing the tubes with active agents for the polymer nanocomposites, household products, cosmetics, agriculture, and pharmaceutical industries. The Company designs, manufactures and sells custom designed error prevention/safety checklist boards.
The Company competes with Air Products and Chemicals, BASF, Dow, E.I. DuPont de Nemours & Company, Applied Minerals, Davis International and Imagexpress.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Naturalnano Inc (OTCMKTS: NNAN), Global Payout, Inc (OTCMKTS: GOHE) and Blue Water Global Group Inc (OTCBB: BLUU) were either jumping higher or diving lower yesterday. To complicate matters for investors, two of these small cap stocks have been subjects of disclosures about paid promotion or investor relation campaigns. So what will these three small caps do for the rest of this week? Here is a closer look to help you decide on a trading or investing strategy:
No comments:
Post a Comment